4-bromo-1-ethylpyridin-2-one | 832735-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-bromo-1-ethylpyridin-2-one
• 英文别名: 4-bromo-1-ethylpyridin-2(1H)-one；4-bromo-1-ethyl-1,2-dihydropyridin-2-one
• CAS: 832735-58-7
• 化学式: C₇H₈BrNO
• 分子量: 202.051
• InChiKey: QOPDNHSCIIQOBK-UHFFFAOYSA-N

物化性质

• 沸点：
  272.0±33.0 °C(Predicted)
• 密度：
  1.547±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-bromo-1-ethylpyridin-2-one 在 sodium hydrogen sulfide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以77%的产率得到1-ethyl-4-sulfanylpyridin-2-one
  参考文献：
  名称：

  [EN] ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
  [FR] DÉRIVÉS DE QUINAZOLINE ALCYNE SERVANT D'INHIBITEURS D'ERBB2

  摘要：

  本公开涉及一般用于抑制ErbB2的化合物及其组合物，包括ErbB2的突变形式，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症中的应用，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食道癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结直肠癌、肾癌、膀胱癌或前列腺癌。

  公开号：

  WO2022006386A1
• 作为产物：
  描述：

  2-氨基-4-溴吡啶 在 硫酸 、 sodium hydride 、 sodium nitrite 作用下， 以 四氢呋喃 为溶剂， 反应 16.25h， 生成 4-bromo-1-ethylpyridin-2-one
  参考文献：
  名称：

  Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants

  摘要：

  Despite the initial benefit demonstrated in clinical setting with ALK inhibitors, the challenging resistant mutants (F1174L, L1196M and G1202R) invariably developed. In this work, a series of 2-aminopyridine derivatives were designed and synthesized by C-5 position incorporation of a 2-pyridone moiety and bioisosteric replacement of the C-3 position linkers. Optimization of the 2-aminopyridine derivatives led to the identification of hit 18d displaying a significant growth inhibition against a variety of ALK-addicted cancer cells. Especially in the case of ALK-positive Karpas-299 cell, 18d exhibited excellent anti-proliferative potency with an IC50 value of about 40 nM. Moreover, 18d demonstrated encouraging activities against wild-type ALK (19 nM), ROS1 (2.3 nM) as well as challenging crizotinib-resistant ALK(L1196M) and ALK(G1202R) mutants with IC50 values of 45 nM and 22 nM, respectively. Additionally flow cytometric analysis indicates that 18d inhibited Karpas-299 cell viability via G1 phase arrest. Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants. (C) 2019 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2019.111734

文献信息

• Condensed derivatives of imidazole useful as pharmaceuticals
  申请人：LABORATOIRE BIODIM

  公开号：EP2913330A1

  公开（公告）日：2015-09-02

  The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

  该发明涉及化合物（I）及其酸盐和碱盐： 其中： 虚线表示双键； X为N或C-R1，Y为N或C-R2，X和Y不同时为N； A选自苯基、萘基和（5-11）成员单环或双环不饱和环或杂环，可能按申请中定义进行取代， A还可以包括另一个（4-7）成员杂环，该杂环为单环、融合、饱和或不饱和，多环系统则包括最多14个成员和最多5个N、O和S中选择的杂原子； B为氢或按申请中定义的取代基，或 B为含有1-3个N、O和S中选择的杂原子的（4-10）成员单环或双环饱和或不饱和杂环，并可能按申请中定义进行取代； 当X为N且Y为C-R2时，B不是氢； R1为氢或按申请中定义的取代基； B和R1不能同时为氢； R2为氢或卤素； 它们的制备，它们在抗菌预防和治疗中的用途，单独或与抗菌药物、抗毒力剂或增强宿主先天免疫力的药物联合使用，以及含有它们的药物组合物和联合物。
• [EN] SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDONE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014081617A1

  公开（公告）日：2014-05-30

  The present invention is directed to substituted pyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及取代吡啶酮化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• [EN] NRF2 REGULATORS<br/>[FR] RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015092713A1

  公开（公告）日：2015-06-25

  The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

  这项发明涉及双芳基类似物，含有它们的药物组合物以及它们作为Nrf2调节剂的用途。
• [EN] INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES<br/>[FR] INHIBITEURS DE RÉPLICATION VIRALE, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：BIODIM LAB

  公开号：WO2014057103A1

  公开（公告）日：2014-04-17

  Inhibitors of viral replication of formula (I), their process of preparation and their therapeutical uses. The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

  抑制病毒复制的化合物（I）及其制备过程和治疗用途。本发明涉及化合物，其在治疗或预防病毒性疾病，包括HIV方面的用途。
• [EN] HERBICIDAL PYRIDAZINUM BASED COMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES À BASE DE PYRIDAZINUM
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2020161270A1

  公开（公告）日：2020-08-13

  Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

  式(I)的化合物，其中取代基如权利要求1中定义的那样，可用作杀虫剂，特别是除草剂。